- Home
- KPTI vs SWZ Comparison
KPTI vs SWZ Comparison
Compare KPTI & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- SWZ
- Stock Information
- Founded
- KPTI 2008
- SWZ 1986
- Country
- KPTI United States
- SWZ United States
- Employees
- KPTI N/A
- SWZ N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- SWZ Finance Companies
- Sector
- KPTI Health Care
- SWZ Finance
- Exchange
- KPTI Nasdaq
- SWZ Nasdaq
- Market Cap
- KPTI 121.2M
- SWZ 112.8M
- IPO Year
- KPTI 2013
- SWZ N/A
- Fundamental
- Price
- KPTI $0.89
- SWZ $8.77
- Analyst Decision
- KPTI Strong Buy
- SWZ
- Analyst Count
- KPTI 4
- SWZ 0
- Target Price
- KPTI $5.00
- SWZ N/A
- AVG Volume (30 Days)
- KPTI 858.7K
- SWZ 14.2K
- Earning Date
- KPTI 10-31-2024
- SWZ 01-01-0001
- Dividend Yield
- KPTI N/A
- SWZ 6.59%
- EPS Growth
- KPTI N/A
- SWZ N/A
- EPS
- KPTI N/A
- SWZ N/A
- Revenue
- KPTI $145,668,000.00
- SWZ N/A
- Revenue This Year
- KPTI $6.41
- SWZ N/A
- Revenue Next Year
- KPTI $11.85
- SWZ N/A
- P/E Ratio
- KPTI N/A
- SWZ N/A
- Revenue Growth
- KPTI N/A
- SWZ N/A
- 52 Week Low
- KPTI $0.62
- SWZ $7.12
- 52 Week High
- KPTI $1.95
- SWZ $8.57
- Technical
- Relative Strength Index (RSI)
- KPTI 62.92
- SWZ 46.48
- Support Level
- KPTI $0.71
- SWZ $8.76
- Resistance Level
- KPTI $0.94
- SWZ $9.14
- Average True Range (ATR)
- KPTI 0.07
- SWZ 0.10
- MACD
- KPTI 0.02
- SWZ -0.02
- Stochastic Oscillator
- KPTI 78.86
- SWZ 41.27
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, and retail.